Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.39) by 5.13 percent. This is unchanged from the same period last year. The company reported quarterly sales of $350.000 thousand which missed the analyst consensus estimate of $872.727 thousand by 59.90 percent. This is a 48.30 percent decrease over sales of $677.000 thousand the same period last year.